GlassScriptPhysician profile
Assad Sattar
NPI 1154554590
$2,732.81
in general payments reported to CMS, 2019-2025
22 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $42.29 · 2021: $275 · 2022: $307 · 2023: $676 · 2024: $492 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $577.53 | 2019-2023 | Diamondback Peripheral |
| Novartis Pharmaceuticals Corporation | $411.51 | 2019-2025 | |
| Abbott Laboratories | $276.74 | 2023-2025 | Diamondback Peripheral, Esprit, Perclose Prostyle |
| Cordis US Corp. | $247.41 | 2023-2025 | Brite Tip Radianz, Mynxgrip, Wizdom |
| Boston Scientific Corporation | $204.89 | 2022-2025 | Peripheral Rotalink Plus, Watchman Flx |
| Amgen INC. | $131.69 | 2019-2024 | Repatha |
| Kestra Medical Technology Services, INC. | $119.05 | 2023 | Assure Wcd |
| Bard Peripheral Vascular, INC. | $107.25 | 2021-2024 | Venclose Maven Catheter |
| E.R. Squibb & Sons, L.L.C. | $103.21 | 2021-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $87.54 | 2020-2024 | Wainua, Farxiga |
| Merck Sharp & Dohme LLC | $87.34 | 2022-2024 | Verquvo |
| Philips North America LLC | $74.08 | 2023 | |
| Janssen Pharmaceuticals, INC | $69.84 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.45 | 2021-2024 | Jardiance |
| Preventice Services, LLC | $51.90 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $23.98 | 2021-2022 | |
| Medtronic, INC. | $23.91 | 2025 | Closurefast |
| Edwards Lifesciences Corporation | $19.93 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.70 | 2023 | |
| Pfizer INC. | $14.97 | 2019 | |
| Novo Nordisk INC | $14.56 | 2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Assad Sattar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.